Researchers at Tufts University and University of Houston System have identified receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) and/or nucleotide-binding oligomerization domain-containing protein 2 (NOD2) inhibitors reported to be useful for the treatment of multiple sclerosis.